SOURCE: Rosetta Genomics

March 07, 2007 12:37 ET

Rosetta Genomics Ltd. Announces Closing of Underwriters' Over-Allotment Option

REHOVOT, ISRAEL and NORTH BRUNSWICK, NJ -- (MARKET WIRE) -- March 7, 2007 -- Rosetta Genomics Ltd. (NASDAQ: ROSG) announced today that it closed the sale of an additional 562,500 ordinary shares pursuant to the full exercise of the over-allotment option granted to the underwriters of its initial public offering. With the closing of the purchase of the over-allotment shares, a total of 4,312,500 ordinary shares were sold by Rosetta Genomics in the offering, resulting in gross proceeds of $30.2 million, before commissions and expenses, and net proceeds of $26.2 million.

C.E. Unterberg, Towbin, LLC acted as the lead manager and the sole bookrunner for this offering. Oppenheimer & Co. Inc. was co-manager for this offering.

Copies of the final prospectus related to the offering may be obtained from C.E. Unterberg, Towbin's syndicate department at 350 Madison Avenue, 10th Floor, New York, New York 10017 (telephone: (212) 389-8056).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Rosetta Genomics

Rosetta Genomics is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs, which are believed to play an important role in regulating protein production. Rosetta has developed an early and strong intellectual property position related to the development and commercialization of microRNA-based products. Rosetta's current programs are focused on the development of microRNA-based diagnostic and therapeutic products for various cancers and infectious diseases.

Contact Information

  • Contact:
    Media & Investors
    Ron Kamienchick
    T: 972-8-948-4785
    Email Contact